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Human ryanodine receptor 2 (hRyR2) mediates calcium
release from the sarcoplasmic reticulum, enabling cardio-
myocyte contraction. The N-terminal region of hRyR2 (amino
acids 1–606) is the target of >30 arrhythmogenic mutations
and contains a binding site for phosphoprotein phosphatase 1.
Here, the solution and crystal structures determined under
near-physiological conditions, as well as a homology model of
the hRyR2 N-terminal region, are presented. The N-terminus
is held together by a unique network of interactions among its
three domains, A, B and C, in which the central helix (amino
acids 410–437) plays a prominent stabilizing role. Importantly,
the anion-binding site reported for the mouse RyR2
N-terminal region is notably absent from the human RyR2.
The structure concurs with the differential stability of
arrhythmogenic mutations in the central helix (R420W,
I419F and I419F/R420W) which are owing to disparities in
the propensity of mutated residues to form energetically
favourable or unfavourable contacts. In solution, the
N-terminus adopts a globular shape with a prominent tail
that is likely to involve residues 545–606, which are unresolved
in the crystal structure. Docking the N-terminal domains into
cryo-electron microscopy maps of the closed and open RyR1
conformations reveals C atom movements of up to 8 A˚ upon
channel gating, and predicts the location of the leucine–
isoleucine zipper segment and the interaction site for
spinophilin and phosphoprotein phosphatase 1 on the RyR
surface.
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1. Introduction
Ryanodine receptors (RyRs) are large homotetrameric
calcium-permeant ion channels in the membrane of the
endoplasmic/sarcoplasmic reticulum (ER/SR). The isoforms
RyR1 and RyR2 are expressed primarily in skeletal and
cardiac muscle, respectively, while the RyR3 isoform is more
widely expressed (Sorrentino & Volpe, 1993). Cardiac RyR2
channels open in response to the action potential during
systole and mediate excitation–contraction coupling by
effecting massive release of calcium ions from the SR lumen
into the cytosol of cardiac myocytes (Bers, 2002). During
diastole, RyR2 activity is very low and produces a small
diastolic calcium leak (Bers, 2002). Genetic diseases leading to
cardiac arrhythmia [catecholaminergic polymorphic ventri-
cular tachycardia (CPVT1) and arrhythmogenic right ventri-
cular dysplasia (ARVD2)] are caused by RyR2 mutations that
increase the diastolic calcium leak (Durham et al., 2007; Yano
et al., 2006).
The RyR2 ion-conducting pore is located at the C-terminal
end of the protein (Bhat et al., 1997); however, >30
arrhythmogenic mutations (http://www.fsm.it/cardmoc/) are
located within the N-terminal region (amino acids 77–466;
George et al., 2007). Likewise, mutations in the RyR1 N-
terminal region cause skeletal muscle diseases, malignant
hyperthermia and central core disease (Durham et al., 2007).
A peptide corresponding to amino acids 163–195 of RyR2 (in
which five disease-causing mutations are found) binds to RyRs
and activates diastolic calcium release (Tateishi et al., 2009). In
RyR1, activation of calcium release by a peptide from the
central region (amino acids 2442–2477) is suppressed by the
N-terminal peptide DP3 (amino acids 324–351; Yamamoto et
al., 2000). Therefore, it has been proposed that in both RyR1
and RyR2 the N-terminal region allosterically regulates
channel activity by interacting with the central part of the
protein.
It is known that the RyR N-terminal region contains three
domains named Ins145_P3_rec, MIR and RIH according to
the Pfam database (Bauerova´-Hlinkova´ et al., 2011). These
domains are conserved in RyR channels and inositol
trisphosphate receptor channels (IP3Rs). In the latter, the
domains are responsible for binding of the agonist inositol
trisphosphate. One of the prerequisites to understand the role
of the N-terminal region in regulating the activity of RyRs is
solution of its structure at the atomic level. In contrast to those
of the IP3Rs (Lin et al., 2011) and the skeletal RyR1 isoform
(Tung et al., 2010), the structure of this region of RyR2 was not
available until recently (Kimlicka, Tung et al., 2013). The slow
progress in the purification and crystallization of the RyR2
N-terminal region has been attributed to the presence of a
chloride-binding site in the cardiac RyR2 that required the
presence of supraphysiological chloride concentrations for
protein solubility (Kimlicka, Tung et al., 2013).
Here, we present the X-ray and SAXS structures of the
human RyR2 N-terminal fragment encompassing amino acids
1–606 (hRyR21–606) obtained at physiological chloride levels.
No Cl anion was found in hRyR21–606 and the structure did
not show any evidence of a chloride-binding site as had been
observed in the mouse RyR21–547 structure (Kimlicka, Tung et
al., 2013). Pronounced differences between hRyR21–606 and
the chloride-containing mRyR21–547 were found at their A/B,
B/C and A/C interfaces, notably in the region of the proposed
chloride-binding site (Kimlicka, Tung et al., 2013). The
hRyR21–606 structure was docked into the cryo-electron
microscopy (cryo-EM) map of the native RyR1 to shed light
on its interactions with other domains and with the associated
regulatory protein phosphoprotein phosphatase 1 (PP1). To
understand the role of Ile419 and Arg420 located in the
central helix (amino acids 410–437) we used circular-dichroism
(CD) spectroscopy, thermal shift assay and analytical gel
filtration to characterize their mutations I419F, R420W and
I419F/R420W.
2. Materials and methods
2.1. Crystal structure
Preparation of hRyR21–606 protein, crystallization, data
collection and processing have been described in detail in
Borko et al. (2013). Substitution mutants were prepared using
the QuikChange protocol (Stratagene). Crystals formed in
hanging drops from a solution consisting of 20 mM Tris–HCl
pH 7.5, 150 mM NaCl, 10% glycerol, 7 mM -mercapto-
ethanol, 1 mM CHAPS, 0.1% betaine mixed with reservoir
solution (100 mM HEPES pH 6.9, 200 mM ammonium
formate, 21% PEG 3350) in a 2:1 ratio.
Data were collected to 2.39 A˚ resolution at 100 K at the
BESSY II synchrotron-radiation source, Berlin, Germany
using 15% ethylene glycol as cryoprotectant. Data collection
was performed using a MAR345dtb image plate. Data were
processed with iMosflm (Powell et al., 2013) and were scaled
by SCALA (Evans, 2011). The crystals belonged to space
group P42212, with unit-cell parameters a = 75.45, b = 75.45,
c = 248.84 A˚,  =  =  = 90 and one molecule in the asym-
metric unit (Borko et al., 2013). The structure was solved by
molecular replacement with MOLREP (Vagin & Teplyakov,
2010) using oRyR11–559 (PDB entry 2xoa; Tung et al., 2010) as
a search model. The structure was built using Buccaneer
(Emsley & Cowtan, 2004) and refined with REFMAC 5.6.0117
(Murshudov et al., 2011) including TLS refinement (Winn et
al., 2001). Three TLS groups (10–223, 224–408 and 409–544)
were used. Refinement of the structure was altered by
inspecting the map, correcting the amino-acid sequence and
manually building the parts that were not built by Buccaneer.
Water molecules were automatically built by Coot (Emsley &
Cowtan, 2004) into electron densities at a 1 level that were
at hydrogen-bonding distances from protein atoms or other
water molecules. Data-collection and refinement statistics of
the hRyR21–606 structure are summarized in Table 1.
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Table 1
Structure solution and refinement.
Values in parentheses are for the outer shell.
Resolution range† (A˚) 44.77–2.39 (2.449–2.39)
Completeness† (%) 99.4
 Cutoff 2.0
No. of reflections, working set 27960 (1598)
No. of reflections, test set 1444 (74)
Final Rcryst 0.224 (0.336)
Final Rfree 0.261 (0.334)
Coordinate ESU based on R/Rfree (A˚) 0.316/0.240
Cruickshank DPI 0.316
No. of non-H atoms
Protein 3934
Ligand 0
Water 79
Total 4013
R.m.s. deviations ()
Bonds (A˚) 0.008 (0.019)
Angles () 1.185 (1.946)
Chiral centres (A˚3) 0.082 (0.200)
Planar groups (A˚) 0.004 (0.020)
Average B factors (A˚2)
Protein 37.7
Main chain 36.9
Side chain 38.6
Water 47.2
Wilson plot B factor (A˚2) 50.4
Ramachandran plot
Most favoured (%) 93.1
Additionally allowed (%) 6.1
Outliers (%) 0.8
† From Borko et al. (2013).
2.2. Quality of the final protein model
Crystal structure refinement (Table 1) converged with R
and Rfree of 22.4 and 26.1%, respectively. The refined model
had good geometry with r.m.s.d.s from ideal bond lengths and
angles of 0.008 A˚ and 1.180, respectively. The estimated
overall coordinate error based on maximum likelihood (ESU)
was 0.205 A˚. The Ramachandran diagram (RAMPAGE;
Lovell et al., 2003) showed that 99.2% of residues were in the
allowed regions (Table 1). The average B factor for main-chain
atoms and for all atoms was 36.9 and 37.7 A˚2, respectively. The
Wilson plot B factor was 50.4 A˚2. The bar diagram (Fig. 1)
shows the temperature factors for C atoms as a function of
residue number. The average B factor for main-chain atoms
and for all atoms was 36.9 and 37.9 A˚2, respectively. The
Wilson plot B factor was 50.4 A˚2.
2.3. Small-angle X-ray scattering structure
The sample was prepared according to Borko et al. (2013).
The sample quality was tested by dynamic light scattering
(DLS; Zetasizer Nano-S) and size-exclusion chromatography
(SEC; GE A¨KTA FPLC, Superose 12
HR10/30) at 5–10C. Prior to SAXS
data collection the protein sample was
diluted at ratios of 1:1, 1:2, 1:3, 1:4 and
1:5 with the sample buffer without
detergents. The protein concentration
during the measurement was in the
range 2–10 mg ml1. SAXS data were
collected on beamline X33, DESY,
Hamburg (see Supporting Information1
for beamline characteristics). The
SAXS data were processed with
programs from the ATSAS 2.5 package
(Supplementary Fig. S1). Initial
processing and analysis were performed
with PRIMUS (Konarev et al., 2003).
The radius of gyration (Rg) was esti-
mated by Guinier approximation and
from the pair-distribution function P(r).
Information about the degree of protein
disorder was obtained from the Kratky
plot. The particle volume was calculated
using the Porod invariant and the
molecular weight was estimated from
the Porod volume. Ab initio modelling
was performed with GASBOR (Svergun
et al., 2001) using ten repetitions with
one scattering curve, with 2 between
0.9 and 1. The normalized spatial
discrepancy (NSD) of all models was
compared using DAMSEL (Volkov &
Svergun, 2003). The average NSD was
1.50  0.07.
2.4. Biophysical analysis
A thermal shift assay was performed
using an iCycler IQ5 PCR Thermal Cycler (Bio-Rad) operated
with the IQ5 software v.2.1 using a 1:1000 dilution of the
5000 SYPRO Orange (Invitrogen) protein dye solution and
5 mg protein in 25 ml buffer. The initial and final holding steps
were set to 10 s at 20 and 80C, respectively; the ramp incre-
ment was set to 1C and the scanning time to 10 s. CD spectra
were collected at 4–40C at a protein concentration of
’15 mM using an Aviv Model 215 instrument (Aviv Biome-
dical Inc., Lakewood, New Jersey, USA) with a 0.01 or 0.02 cm
path-length cell. Detailed information is in the Supporting
Information. Secondary-structure content was estimated using
the CDSSTR (Johnson, 1999) algorithm as implemented on
DichroWeb (Whitmore & Wallace, 2008) using the SP175
reference spectra (Lees et al., 2006).
2.5. Modelling the missing residues
Homology models of hRyR21–606 that contained all resi-
dues, including those missing from the X-ray structure, were
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Figure 1
Temperature factors of C atoms as a function of residue number. The secondary-structure elements
are shown as rectangles (blue, -sheet; red, -helix). The central -helix is shown in purple. The gaps
represent residues that are missing in the structure. Domains are indicated by double arrows (A,
blue; B, green; C, red).
Figure 2
A stereoview of the 4jkq structure. The figure shows the C trace of the hRyR21–606 structure
consisting of the three domains A (blue), B (green) and C (red) and the central helix (amino acids
410–437; purple).
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: LV5073).
built with the I-TASSER protein structure and function
prediction server (http://zhanglab.ccmb.med.umich.edu/
I-TASSER/; Roy et al., 2010). The confidence score (C-score),
based on the quality of threading alignments and the
convergence of structural assembly refinement simulations,
was used for estimating the accuracy of structure predictions.
The crystal structures of the N-terminal three domains of
skeletal muscle RyR1 (PDB entry 2xoa; Tung et al., 2010) and
the ligand-binding domain of an InsP3 receptor (PDB entry
3t8s; Lin et al., 2011) were used as templates. Of the five
resulting models, the one with an extended C-terminus
imitating the shape of the SAXS envelope (C-score of 2.88)
was used for docking into the envelope. The I-TASSER model
with the best C-score of 0.10 was used for completing the
final model (PDB entry 4jkq) with the residues missing in the
X-ray structure. The resulting model was minimized in
Chimera (Pettersen et al., 2004) and used for docking into the
RyR1 cryo-EM maps. Figures were prepared using Chimera
unless indicated otherwise.
2.6. Docking the hRyR21–606 structure into SAXS and
cryo-EM electron-density maps
The SAXS structure was transformed into an electron-
density map with a resolution of 9.38 A˚ using pdb2vol from the
SITUS 2.7 package (Wriggers, 2010). The hRyR21–606 crystal
structure was docked into the SAXS envelope using colores
(SITUS 2.7). The hRyR21–606 homology model with the
C-terminal tail (amino acids 519–606) was docked manually
into the SAXS envelope. Cross-correlation was maximized by
collage (SITUS 2.7). The shapes of the predicted atomic
structure of hRyR21–606 and the SAXS envelope were
compared by CRYSOL from the ATSAS 2.5 package, giving a
2 of 2.72. Docking of the hRyR21–606 crystal structure, its
individual domains and the homology model into cryo-EM
maps of RyR1 was performed by colores using Laplace
filtering.
3. Results
3.1. Overview of the hRyR21-606 crystal structure
The structure of hRyR21–606 determined at 2.39 A˚ consists
of three domains: A (residues 10–223) and B (224–408)
adopting a -trefoil fold, and C (409–544) formed by a bundle
of five -helices (Fig. 2). Domains A and B correspond to the
Pfam domains Ins145_P3_rec and MIR, and domain C
includes the RIH domain. The first -helix of domain C
(referred to as the central helix) is positioned in the centre of
the structure and forms contacts with all three domains. This
helix is not part of the RIH domain (amino acids 451–655;
Bauerova´-Hlinkova´ et al., 2011). The alignment between
N-terminal sequences, secondary-structure elements and
unresolved residues of the present hRyR2 structure (PDB
entry 4jkq; amino acids 1–606), with the homologous struc-
tures of rabbit RyR1 (2xoa; amino acids 1–559; Tung et al.,
2010) and mouse RyR2 (4l4h; amino acids 1–547; Kimlicka,
Tung et al., 2013) is shown in Figs. 3(a) and 3(b). Residues 1–9,
79–106, 379–386 and 545–606 are not visible in the hRyR21–606
structure. The high B-factor values for C atoms (Fig. 1)
represent segments of the structure which are likely to be
highly flexible owing to the absence of their binding partners
present in the native hRyR2. High flexibility is also respon-
sible for the gaps in the structure where electron density was
not interpretable.
The hRyR21–606 molecule contains ten cysteine residues, of
which the two pairs Cys36/Cys65 and Cys131/Cys158 are well
positioned to form disulfide bonds; no S–S bridge could be
seen in the structure, which might be owing to the presence of
-mercaptoethanol (7 mM), which was used during purifica-
tion and crystallization.
Differences between the N-terminal structures of hRyR2
and those of mRyR2 and oRyR1 are analysed in detail in
Table 2. Here, the deviations between C atoms of the three
analysed structures superimposed either as a whole or by their
individual domains are shown. The rows in the table show the
differences in the relative position of a given region of the
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Table 2
Superposition of hRyR21–606 (PDB entry 4jkq) with mRyR21–547 (PDB entry 4l4h) and oRyR11–559 (PDB entry 2xoa) based on C atoms present in all
three structures.
Column headings indicate parts of the sequences (whole chains, A–A, B–B or C–C) used for superposition, for which only C atoms  2 A˚ apart were used; row
headings indicate parts of the sequences (whole chains, A/A, B/B/ or C/C), for which an r.m.s.d. was calculated. R.m.s.d. and maximal deviations were calculated
from all C atoms of equivalent residues present in all three structures. Assignment of domains (hRyR2 numbering): A, 10–223; B, 224–408; C, 409–544.
Superposition of 4jkq and 4l4h Superposition of 4jkq and 2xoa
Domains Domains
Whole chains A–A B–B C–C Whole chains A–A B–B C–C
R.m.s.d. (A˚)
Whole chains 2.1 3.5 2.7 2.9 2.2 2.6 2.6 2.5
A/A 1.7 0.8 2.9 3.5 1.3 1.0 2.6 2.6
B/B 3.0 4.5 2.9 3.1 3.2 3.7 3.1 3.1
C/C 1.1 4.4 2.0 0.4 1.1 2.6 1.6 0.8
Rotation angle between superposed structures () 0.7 6. 7 3.7 4.6 0.6 4.1 3.3 2.5
Maximum deviation (A˚) 24.0 3.8 23.7 2.5 24.5 4.9 24.4 8.4
Most deviating residue (hRyR2 numbering) Gly348 Asn198 Gly348 Glu473 Gly348 Ala223 Gly348 Ala440
No. of superposed atoms 387 157 150 112 403 158 144 107
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Figure 3
Alignment of N-terminal RyR regions. (a) hRyR21–606 and oRyR11–559, (b) hRyR21–606 and mRyR21–547. Identical amino acids are in bold. Secondary-
structure elements determined from the X-ray structures are shown as arrows (-strands) and helices. Blue, green and red colours indicate the residues
that are missing in 4jkq, 4l4h and 2xoa, respectively. Missing side chains are boxed.
three compared structures, characterized by the r.m.s.d. of
their C atoms after the superposition of individual
substructures. As expected, the r.m.s.d.s are the smallest when
the same regions are both superimposed and compared (bold
numbers), and show that while domains A and C are struc-
turally very similar in all three structures, there are large
differences between the structures of domain B. The largest
difference is in the region of the long loop composed of
residues 333–361 in domain B, which is only partially resolved
in 4l4h and 2xoa. Columns in the table show the effect of
superimposing a given region on the r.m.s.d. of the other
regions. Superposition of the A domains of 4l4h and 2xoa onto
4jkq has the largest effect on the relative position of the
remaining regions. It leads to a significant increase of the
r.m.s.d. between the other corresponding domains by up to
3 A˚ and results in rotation of the structures 4l4h and 2xoa by
2.5–6.7 relative to the structure 4jkq. A similar shift of the
relative position of domains A and B is observed when
domains C are superimposed. The effect of superimposing
domain B is less prominent. Superposition of the structures
based on domain A is also illustrated in Supplementary
Fig. S2.
Upon docking the hRyR21–606 structure into RyR cryo-EM
maps (see Supporting Information), four symmetrical copies
of the structure form the central rim of the RyR (Supple-
mentary Movie S1), as previously reported for 2xoa (Tung et
al., 2010). Individual faces of the structure are shown relative
to their positions in the whole RyR molecule, with the top and
bottom surfaces pointing to the cytoplasm and to the SR
membrane, respectively.
3.2. Electrostatic potential distribution
Despite a high sequence identity and similarity of the X-ray
structures of hRyR21–606, mRyR21–547 and oRyR11–559, their
overall net charge calculated in vacuo differs and reaches
values of 9, 13.9 and 5, respectively. This discrepancy is
caused by the absence of 33 residues and 41 side chains in the
mRyR21–547 structure and approximately the same number of
residues and 19 side chains in oRyR11–559 located predomi-
nantly on the surface, which are present in the hRyR21–606
structure. Thus, the calculated charges of the mRyR21–547 and
oRyR11–559 structures substantially differ from the true value.
We have analysed the electrostatic potential distribution of
hRyR21–606 homotetramer interfaces (Figs. 4a, 4b and 4c).
Figs. 4(b) and 4(c) show a detailed view of the surfaces of
domains A (Fig. 4b) and B (Fig. 4c) that participate in the
intermonomer interaction. The interacting surfaces of
domains A and B show a prevalence of positive and negative
potentials, respectively, suggesting a significant role of elec-
trostatic interactions in RyR2 central rim tetramerization.
3.3. Interdomain interfaces and the putative chloride-binding
site
Analysis of the interfaces between domains A/B, A/C and
B/C is shown in Table 3. Most of the interactions between
domains A/C and B/C involve the central helix, strongly
suggesting a significant role of this helix in maintaining the
integrity of the N-terminal fragment. For all three interdomain
interfaces in hRyR21–606, the juxtaposed protein surfaces have
complementary electrostatic potentials (Figs. 4d, 4e and 4f),
suggesting an important role of polar and charged interactions.
The interdomain A/B/C interactions in hRyR21–606 notably
differ from those in mRyR21–547 owing to the presence of a
Cl anion in the latter (Figs. 5a and 5b). As a result, the side
chains of Glu40, Tyr125, Arg276 and Arg417 in hRyR21–606
adopt different conformations from those in mRyR21–547.
Thus, the N atoms of Arg417 are within hydrogen-bonding
distances of carboxyl O atoms of the domain A aspartate,
glutamate and serine (Asp61 OD2, Glu40 OE2 and
Ser63 OG). The Arg420 NH1 atom forms a hydrogen bond to
the main-chain O atom of Val300 and Arg298 NH1 of domain
B. Moreover, the guanidine group of Arg420 makes a face-to-
face stacking interaction with that of Arg298. All of the above-
mentioned contacts indicate the importance of Arg417 and
Arg420 for maintaining a stable A/B/C domain arrangement
in the hRyR21–606 structure (Figs. 5a and 5b). The importance
of the central helix is apparent also from its relatively low B
factors (Fig. 1).
The electrostatic interactions between domains A, B and C
observed in the present structure are replaced in the
mRyR21–547 structure (Kimlicka, Tung et al., 2013) by contacts
of Arg420, Arg298 and Arg276 with a Cl anion, for which
the authors proposed a crucial role in mediating inter-
domain interactions and the stability of the whole structure.
Significantly, despite the presence of chloride anions in our
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Table 3
Interfaces between RyR N-terminal domains A, B and C.
4jkq 4l4h 2xoa
Interface A/B A/C B/C A/B A/C B/C A/B A/C B/C
Interface area†‡ (A˚2) 812 475 561 761 323 576 758 429 557
No. of residues at the interface 23/24 14/14 18/16 25/24 10/14 14/18 24/21 14/14 17/15
Surface complementarity 0.69 0.65 0.57 0.58 0.67 0.48 0.58 0.75 0.63
Hydrogen bonds‡ 5 7 (4) 6 (5) 8 8 (5) 8 (6) 7 9 9
Salt bridges‡ 3 7 (4) 3 (2) 1 1 3 1 3 3
G of interaction ‡ (kcal mol1) 5.2 0.2 (+1.4) 1.9 (1.6) 8.0 0.2 0.8 6.4 1.4 3.4
† The assignment of domains is as follows. oRyR1: A, 1–205, B, 206–395; C, 396–532. hRyR2, mRyR2: A, 1–223; B, 224–408; C, 409–544. ‡ Determined by PISA (http://www.ebi.ac.uk/
msd-srv/prot_int/cgi-bin/piserver). Only hydrogen bonds of <3.5 A˚ were accepted. Values for interaction between the central helix and domains A and B are in parentheses.
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Figure 4
Electrostatic potential distribution of hRyR21–606 surface. (a) A view of the four monomers of hRyR21–606 that form the central rim of the RyR, with one
of the monomers showing the potential distribution. Domains A, B and C are shown in blue, green and red, respectively. (b) A view of the potential
distribution (blue, positive; red, negative) of the surface of domain A that interacts with domain B of the neighbouring hRyR21–606 monomer (green
ribbon). (c) A view of the potential distribution of the surface of domain B that interacts with domain A of the neighbouring hRyR21–606 monomer (blue
ribbon). (d–f ) Electrostatic potential distribution at the interfaces A/B (d), B/C (e) and A/C ( f ) of hRyR21–606. One side of the interface is shown as a
electrostatic potential surface, while the complementary side is shown as a ribbon (blue, green and red for domains A, B and C, respectively). The two
views were created by a 180 rotation around the vertical axis. Residues with a substantial electrostatic potential are indicated. Most of the interactions
between domains A/C and B/C involve residues from the central helix (Table 3).
crystallization solution (Borko et al., 2013), there was no
electron density in the close proximity of Arg420 in the
hRyR21–606 structure to be assigned to a Cl anion. In contrast
to mRyR21–547, the Arg276 guanidine in hRyR21–606 forms a
hydrogen bond to Glu278 OE2. Furthermore, the OH atoms
of Tyr125 in superimposed hRyR21–606 and mRyR21–547 are
almost 5 A˚ apart. In the hRyR21–606 structure the position of
the Tyr125 side chain of mRyR21–547 is occupied by Arg417
(Fig. 5b).
In oRyR1 (Tung et al., 2010), the equivalent of Arg420 in
hRyR2 is His405, for which the side chain, in contrast to
Arg420, forms neither polar nor charged contacts with the
surrounding residue. While in oRyR1 the hub of the salt-
bridge/hydrogen-bond network stabilizing the A/B/C interface
is formed by Asp61 from the A domain, in
hRyR2 the hub is formed by the tandem of
Arg417 and Arg420 from the central helix
(Fig. 5a). Thus, the interdomain interface
interactions of hRyR2 substantially differ
from other N-terminal RyR structures
known so far.
3.4. Other putative binding sites
Two putative binding sites situated close
to the A/C and A/B/C interfaces have been
reported for mRyR21–547; the electron
density in this region was assigned to PEG
molecules (Kimlicka, Tung et al., 2013).
Despite the use of a rather high PEG 3350
concentration in our crystallization solution
(Borko et al., 2013), no PEG molecules were
identified in the hRyR21–606 structure. In
one of the PEG-binding sites proposed for
mRyR21–547, we find that the side chain of
Phe42 is located at this position in the 4jqk
structure (Fig. 5c). In the region of the other
putative PEG-binding site, no electron
density is present in 4jkq except for a single
water molecule (Fig. 5d).
3.5. Mutations associated with ARVD2 and
CPVT1
The new structural details revealed for
hRyR21–606 enabled assessment of the
potential role of several residues, mutation
of which result in CPVT/ARVD2 (http://
www.fsm.it/cardmoc/). Based on the analysis
of the structure, we could address the likely
effect of mutations L62F, P164S, R169Q,
V186M, I217V, E243K, F329L, R332W,
D400H, R414C/L, T415R, I419F, R420W/Q
and L433P; Supplementary Table S1). Of all
the known residues undergoing arrhythmo-
genic mutations in this region, there is only
one, Met81 located in the dynamic -helix
(Amador et al., 2013), that was not present
in the hRyR21–606 structure.
In all reported structures of the RyR
N-terminal region encompassing the first
	600 amino acids, the central -helix is
prominent. This helix, positioned between
the ABC domains, forms the beginning of
domain C and is not a part of any Pfam-
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Figure 5
Conformation of residues at the putative binding sites of RyR2. (a) A stereoview of the salt-
bridge/hydrogen-bond network of hRyR21–606 stabilizing the A/B/C interface. Hydrogen bonds
are shown as dashed lines. (b) A stereoview of the superposition of the chloride-binding site of
mRyR21–547 (light beige) with the equivalent site of hRyR21–606. There are major differences in
the conformations of the Glu40, Tyr125, Arg276 and Arg417 side chains; the mRyR21–547
chloride anion (indicated) has no equivalent in the hRyR21–606 structure. (c, d) Comparison of
the hRyR21–606 structure close to the A/C interface (c) and the A/B/C interface (d) with the
putative PEG binding sites of the mRyR21–547 structure. In the 4jqk structure, the Phe42 side
chain is located in one of the PEG binding sites found in mRyR21–547 (c). In the region of the
other putative PEG binding site, no electron density is present in 4jkq except for a single water
molecule (d). Residues from domains A, B and C of hRyR21–606 are shown in blue, green and
red, respectively. Residues of mRyR21–547 are shown in light beige. PEG is coloured in grey.
Electron density is drawn at the 1 level. This figure was prepared with PyMOL (Schro¨dinger).
predicted domain (Bauerova´-Hlinkova´ et al., 2011). The
interface of the central helix with the remainder of domain C
is composed of hydrophobic and negatively charged side
chains, while the part facing domains A and B is composed
mostly of hydrophobic and positively charged side chains
(Fig. 6a). The central helix interacts with the surrounding
domains through polar, charged and hydrophobic interactions
(Table 4). In hRyR2, five amino acids in the central -helix are
subject to a total of seven disease-associated mutations
(Fig. 6b and Table 4). These amino acids are actively involved
in the network stabilizing the N-terminus structure (Fig. 6c).
Ile419, which is fully conserved in RyR isoforms from
different mammalian species and exhibits pathogenic muta-
tions in both RyR1 and RyR2, forms contacts with residues of
domain C. Introducing Phe in position of I419 likely causes
severe steric clashes resulting in destabilization of the struc-
ture (Fig. 6c, right inset). The most probable rotamer of Trp in
position of Arg420 should adopt a conformation forming
acceptable contacts with neighbouring residues, thus avoiding
harmful structural changes (Fig. 6c, left inset). Overall, in the
central helix and amino acids that directly precede it (amino
acids 400–409), there is a significantly higher frequency of
arrhythmogenic mutations than in the remainder of the
N-terminal fragment, emphasizing the importance of central
helix integrity for proper RyR2 function.
We have successfully purified the cardiac disease-associated
mutants of hRyR21–606, I419F and R420W, and the double-
mutant I419F/R420W. Thermofluor analysis of I419F and
I419F/R420W (Fig. 7a) showed a decrease in thermal stability
by 	6 and 8C, respectively, compared
with the wild type. The R420W muta-
tion by itself did not induce a significant
change of thermal stability (Fig. 7a).
Size-exclusion chromatography at 4C
showed a propensity of the I419F
mutant to dimerize (a dimer:monomer
ratio of 0:100% and 65:35% for the wild
type and the I419F mutant, respectively;
Fig. 7b).
CD spectra of hRyR21–606 and the
mutant proteins I419F, R420W and
I419F/R420W recorded at 4C are
shown in Figs. 7(c)–7( f). The spectrum
of the I419F mutant was virtually iden-
tical to that of the wild-type protein,
whereas the R420W and I419F/R420W
mutant proteins exhibited slightly lower
amplitudes. Deconvolution of the
spectra resulted in an -helical and
-strand content of 22 and 29%,
respectively, for wild-type and I419F
proteins, whereas the helical content
was estimated to be 	3% lower for the
R420W and I419W/R420W mutants.
The CD-based estimate of secondary
structure for the wild-type protein is in
excellent agreement with that of the
crystal structure, which contains 21.8% -helix and 29.5% -
strands.
CD spectra recorded at increasing temperatures showed
anomalous behaviour: whereas protein unfolding is usually
indicated by a decrease in the absolute amplitude, hRyR21–606
and its variants showed the opposite effect (Figs. 7c–7 f). The
increase in the CD amplitude was accompanied by an increase
in the photomultiplier dynode voltage (insets in Figs. 7c–7 f),
indicative of light scattering owing to the formation of
aggregates. Whereas the wildtype and the double mutant
protein exhibited aggregation at T > 30C, the I419F and
R420W mutants aggregated at T > 20C and T > 35C,
respectively. Besides the central helix mutants we also
analysed P164S and R176Q mutant proteins. Their CD spectra
have shown no deviation from those of wild-type hRyR21–606.
Docking of the X-ray structure and a homology-based
model into the RyR1 cryo-EM map (Supplementary Fig. S3
and Supplementary Movie S1) indicates that domain C cannot
be involved in interaction between hRyR21–606 monomers in
situ; thus dimerization can be viewed as a surrogate for
interaction with another protein sequence outside of the 1–606
region.
3.6. Docking of the crystal structure and its model into the
solution structure
To resolve the topology of the molecule in solution, the
structure of hRyR21–606 was determined by SAXS. A globular
topology was expected; however, the structure was a combi-
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Table 4
Charged, polar and hydrophobic contacts of the central helix residues.
Central helix residues (column I) forming charged, polar and hydrophobic contacts with residues from
domains A, B and C (column II). Abbreviations: ARVD2, arrhythmogenic right ventricular dysplasia type
2; CPVT1, catecholaminergic polymorphic ventricular tachycardia type 1; E-IVF, idiopathic ventricular
fibrillation induced by emotion or exercise; SCD, sudden cardiac death associated with drowning; SUO,
syncope of unknown origin.
I II Distances (A˚) Mutation/disease† Comment
Glu411 Arg485 <3.5 — PSA‡
Glu412 Arg235, Asn409 <3.5 — B/C interface
Arg414 Tyr125 <3.5 R414C, L/SCD, CPVT1,
E-IVF, SUO
A/C interface
Thr415 Tyr462, Glu410 <3.5 T415R/CPVT1 Buried
Arg417 Asp61, Glu40, Arg420 <3.5 — A/C interface
Ile419 Phe489, Met494, Thr415, Ala416,
Leu488, Glu492§
<4.5 I419F/SCD, SUO B/C interface
Arg420 Val300, Ala298, Arg417 <3.5 R420Q, W/CPVT1, ARVD2 B/C interface
Ser421 Glu40 <3.5 — A/C interface
Phe426 Thr422, Val452, Leu456, Leu459,
Leu497, Cys501, Leu553
<4.5 — buried
Arg428 Asp446 <3.5 — PSA
Phe429 Leu433, Val452, Leu447, Ile449,
Cys501, Leu505
<4.5 — Buried
Leu433 Phe429, Phe415, Arg504§, Leu505 <4.5 L433P/ARVD2 Buried
Asp434 Arg504, Lys438 <3.5 — PSA
Leu436 Ala442, Val445, Leu447, Val517,
Ala518
<4.5 — PSA
Lys438 Asp434 <3.5 — PSA
† http://www.fsm.it/cardmoc (Bauce et al., 2002; Choi et al., 2004; Creighton et al., 2006; Medeiros-Domingo et al., 2009;
Nishio et al., 2006; Tester et al., 2004, 2005; Tiso et al., 2001). ‡ Partially solvent accessible. § Hydrophobic part of the
side chain.
nation of a globule and a tail (Fig. 8). Docking of the crystal
structure into the globular part of the SAXS envelope
(Fig. 8a) yielded four best orientations with cross-correlation
coefficients of 0.60–0.64. In the optimal orientation (R = 0.64),
the C-terminus of hRyR21–606 (Gln544) was positioned next to
the tail of the SAXS structure, suggesting that the residues
unresolved in the crystal structure (amino acids 545–606) are
located within the tail.
According to the I-TASSER prediction server, the RIH
domain (amino acids 451–655) is formed by an armadillo motif
composed of -helices. Therefore, it is conceivable that the
incomplete RIH domain is flexible, possibly leading to its
partial unfolding. To verify this possibility, a set of five
homology models of the complete hRyR1–606 sequence was
constructed using the I-TASSER server. One model (C-score
of 2.88) had an extended tail (amino acids 542–606). The
model provided a cross-correla-
tion coefficient of 0.65 after
docking into the SAXS envelope
(Fig. 8b) and gave an acceptable
CRYSOL fit (Supplementary Fig.
S1) to the experimental SAXS
data. Thus, it is highly likely that
the tail observed in the SAXS
structure is formed by the 61 C-
terminal residues (amino acids
545–606) that are unresolved in
the crystal structure.
3.7. Docking the crystal structure
and its model into cryo-EM maps
Docking the hRyR21–606 struc-
ture into cryo-EM maps of the
closed and open RyR1 suggests
that this region undergoes
substantial movement upon
channel opening (Supplementary
Fig. S3 and Supplementary Movie
S1). The distances between
nearby C atoms of neighbouring
hRyR21–606 monomers in the
open conformation were on
average larger by ’3 A˚ than
those in the closed conformation
(Supplementary Table S2).
Different distances between atom
pairs in the closed and open
conformation suggest that the
central rim not only rotates
around and moves away from the
symmetry axis, but that re-
orientation of adjacent N-term-
inal domains relative to each
other also occurs (Supplementary
Movie S1). The shift of C atoms
in the RyR21–606 structures
docked into the closed and open RyR1 cryo-EM maps was on
average 6–7 A˚ for the tested atoms of the exposed surface, but
was only 4 A˚ for the atoms of the interfaces between domains
(Supplementary Table S2). Docking of single domains into the
maps of closed and open RyR1 suggests that the distance
between individually docked A, B and C domains within a
single monomer is longer, and the distance between indivi-
dually docked domains of neighbouring monomers is shorter,
than in 4jkq. Rearrangement of individual domains relative to
each other upon channel gating may occur as well (Supple-
mentary Movie S1).
Docking the homology model into the cryo-EM maps
(Fig. 9) enabled examination of the missing residues relative to
the neighbouring RyR domains. With the exception of resi-
dues 75–109, which formed the two previously predicted
-helices (Bauerova´-Hlinkova´ et al., 2011), the residues absent
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Figure 6
The central helix and its mutations. (a) Position of the central helix amidst the A (blue), B (green) and C
(red) domains. Conformation of the most important amino acids is shown. The ribbon of the central helix is
colour-coded by the properties of the respective amino acids: blue, positively charged; red, negatively
charged; purple, polar; green, hydrophobic. (b) Central helix residues susceptible to mutations associated
with cardiac arrhythmias in the hRyR21–606 structure. (c) The important amino acids forming a charge
network stabilizing the structure. Right inset: the two most probable conformations of Phe419 in the I419F
mutant (rotamers r1 and r2) show clashes with neighbouring residues, explaining the thermal stability
decrease of the structure. Left inset: Arg420 points to solution; this may also occur for R420W in the
mutant, explaining why this mutation has not affected the thermal stability. The closest contacts of Trp420
in the R420W mutant are with the Phe424 side chain (’2.5 A˚) and the Thr302 main chain (’3 A˚). Central
helix amino-acid residues undergoing mutations are coloured as follows: blue, positively charged; red,
negatively charged; purple, polar; green, hydrophobic.
in the A and B domains of 4jkq (amino acids 1–9 and 379–385)
adopted a random-coil conformation in the model. The
C-terminal part, encompassing amino acids 545–606,
continued the armadillo motif of the C domain with three
further -helices. The N-terminal amino acids (1–9) pointed
from the central rim into the channel pore, similar to amino
acids 337–347, residues that were unresolved in previously
published structures but present in the 4jkq structure. Resi-
dues 337–347 interact with residues 1–10 of the same
monomer (Lys344 NZ–Glu8 OE2; Fig. 9a) and of the neigh-
bouring monomer (Lys337 NZ–Asp3 OD1, Asp339 OD1–
Asp3 OD1, Asp339 OD1–Gly5 N, Glu336 OE2–Glu10 OE2;
Fig. 9b). The position of some residues suggested their inter-
action with other parts of the RyR molecules, since they
pointed to or were contained in regions (numbered according
to Serysheva et al., 2008) of the cryo-EM map outside the
central rim: the loop formed by residues 377–387 (Fig. 9c)
pointed from region 2a of the cryo-EM map into region 4, with
a 2.0 A˚ distance between the map surface and CE of Met384.
The C-terminal part of the model (amino acids 545–606),
containing the leucine–isoleucine zipper (LIZ) motif (amino
acids 555–586), was located on the surface of the cryo-EM
map at the interfaces between regions 2b and 3 (Fig. 9d) and
between regions 2b and 5 (Fig. 9e). Significantly, when the
structure of the PP1–spinophilin complex (PDB entry 3egg;
Ragusa et al., 2011) was manually positioned to enable the
previously observed interaction of the spinophilin
(L492ELFPVEL) and RyR2 (L565EASSGIL) sequences (Marx
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Figure 7
Stability of hRyR21–606 and its mutants. (a) Normalized thermal stability curves of hRyR21–606 (blue) and its mutants I419F (red), R420W (violet) and
I419F/R420W (green), measured from 20 to 90C. The transition around 38C (indicated by the arrow) corresponds to the melting of Ile419 dimers. (b)
Analytical SEC profile of hRyR21–606 wild type (blue) and of I419F (red), R420W (purple) and I419F/R420W (green) mutants. The elution maximum at
11.7 ml corresponds to dimers of I419F. Elution maxima at 12.9 ml correspond to the wild type and mutant monomers. (c)–( f ) Far-UV CD spectra of
hRyR21–606 wild type (c) and I419F (d), R420W (e) and I419F/R420W ( f ) mutants recorded at 4C (black), 25C (blue), 30C (orange), 35C (green) and
40C (red). Insets show the ellipticities [] (black) and the dynode voltage difference from the buffer baselinedyn (blue) at 218 nm as a function of the
temperature.
et al., 2001), the PP1–spinophilin complex closely followed the
surface contour of regions 5 and 9 of the cryo-EM map (Fig. 9e
and Supplementary Movie S2). Spinophilin binds to hRyR2
predominantly by hydrophobic interactions, mainly between
Leu565 and Leu572 of hRyR2 and
Phe495 and Val497 of spinophilin.
3.8. Open versus closed structures
The previously published structure of
the N-terminal region of wild-type
mRyR2 differs from that of the mRyR2
R420Q mutant in the relative position
of individual domains (Kimlicka, Tung
et al., 2013 ). The different orientation
of these domains was interpreted as a
weakening of the interaction between
domains A and C and a strengthening
of the interactions between domains B
and C in RyR mutants (Kimlicka, Lau
et al., 2013), by analogy to IP3Rs, in
which the suppressor domain A
decreases the ligand-binding affinity of
the IP3Rs (Lin et al., 2011; Seo et al.,
2012). To understand the possible effect
of domain reorientation on RyR
channel gating, it is important to
distinguish precisely between the ‘open’
and ‘closed’ conformations of the RyR
domains, which were presupposed to be
analogous (Kimlicka, Lau et al., 2013)
to the ligand-bound and ligand-free
conformations of the IP3 receptor
domains, respectively (Seo et al., 2012).
In the IP3R1 receptor, binding of
InsP3 induces a change in the angles
and distances of individual domains. To
gauge the conformational changes upon
RyR gating, we analysed the relative
positions of the A, B and C domains of
the known RyR and IP3R structures
(Table 5). Parameters defining these
positions for both IP3Rs and RyR2s,
which were represented as inertia
ellipsoids, are visualized in Supplemen-
tary Fig. S4. The ‘closed’ and ‘open’
RyR structures were approximated by
docking individual hRyR21–606 domains
into the cryo-EM maps of RyR1 in the
closed (EMD 1606) and open (EMD
1607) states, respectively (Samso´ et al.,
2009). Differences between the ‘open’
and ‘closed’ conformations common to
IP3R and RyR structures were
observed only in the angle , which was
significantly larger in the closed than in
the open conformation of both channels
(Table 5). Significant differences
between RyR structures could be
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Figure 8
Solution structure of hRyR21–606. Crystal structure of hRyR21–606 (a) and the I-TASSER prediction
model (b) fitted into the SAXS envelope. Blue, domain A, INS145_P3_rec; green, domain B, MIR;
purple, central helix; red (amino acids 451–544) and orange (amino acids 545–606), parts of the RIH
domain.
Table 5
Analysis of spatial relationships between domains of the N-terminal RyR and IP3R structures.
RyR IP3R
2xoa 4jkq 4l4h 4l4i
Domains A, B
and C docked
into EMD 1606
Domains A, B
and C docked
into EMD 1607
InsP3, free
(3uj4, 3t8s
chain A )
InsP3, bound
(3uj0, 3t8s
chain B)
Angle of axes† ()
/a1b1 46.7 49.1 56.3 56.5 51.8 51.6 76.3  0.8 82.2  1.6‡
/a1c1 41.9§ 45.8 46.3 46.9 46.1 40.2§ 59.7  1.1 54.2  3.1
/a2b2 92.1 90.6 88.0 85.8 89.9 91.0 42  1.73 51.1  0.46‡
/a3b3 87.1} 84.8 86.5} 85.0 85.0 80.9†† 61.7  1.1 62.8  1.1
/b3c3 85.5†† 94.8 94.0 93.4 95.2 95.2 73.0  2.7 83.6  1.2‡
Distance between centres of gravity (A˚)
A–B 31.1 31.7 31.3 31.3 32.4 36.0†† 35.2  0.1 35.0  0.1
A–C 30.3 30.5 30.7 30.6 30.9 37.5†† 28.8  0.3 29.1  0.02
B–C 30.6 30.4 30.9 30.5 33.2 32.6 31.2  0.1 29.8  0.1‡
Angle‡‡ ()
 59.9 58.4 59.7 58.9 63.3 52.7†† 57.7  0.4 54.2  0.4‡
 58.8 58.9 59.3 59.3 56.1 66.0†† 51.2  0.7 52.4  0.1
 61.3 62.7 61.0 61.7 60.6 61.3 71.1  0.4 73.3  0.4‡
State Closed Closed Closed Closed Closed Open Closed Open
† a, b, c are the axes of the ellipsoids approximating domains A, B and C, respectively. The numbers 1, 2 and 3
correspond to the major, medium and minor axes of the ellipsoids (see Supplementary Fig. S4 for an
illustration). ‡ Different from the InsP3-free structures (p < 0.05, t-test). § Different from 4jkq, 4l4h, 4l4i and
‘closed’ RyR21–606 (p < 0.05, one-way ANOVA). } Different from 4jkq and 4l4i (p < 0.05, t-test). †† Different from
the remaining RyR structures (p < 0.05, one-way ANOVA). ‡‡ , ,  are the angles/BAC,/ABC, and/ACB of the
triangle ABC formed by the centres of the ellipsoids approximating domains A, B and C, respectively.
observed in the angles of the minor axes of domains A and B
(/a3b3), in the distances of domains A and B and of domains
A and C, and also in the angle . In all of the above
measurements, none of the experimentally determined struc-
tures were significantly different from the ‘closed’ RyR
structure but all were different from the ‘open’ RyR structure
(Table 5).
The difference in the A-domain position relative to the C
domain between the 2xoa and the ‘open’ structure on the one
hand and the remaining RyR structures (4jkq, 4l4h and 4l4i;
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Figure 9
The hRyR21–606 homology model docked into a cryo-EM map of the closed RyR1 (EMD 1606). (a, b) Side view of residues 5–10 (blue) and 342–352
(green) of a single monomer (a) and residues 1–12 (blue) and 336–342 (green) of two neighbouring monomers (b) pointing into the channel pore; (c)
oblique view of the flexible loop (amino acids 377–387, green); (d) top view of the C-terminus (amino acids 545–606, red) containing the LIZ motif
(amino acids 555–586) with the amino acids (L565EASSGIL) that interact with spinophilin shown in orange. (e) Oblique view of the above LIZ motif with
attached complex of spinophilin (PDB entry 3egg chain C, pink; L492ELFPVEL, purple) with PP1 (PDB entry 3egg chain A, green). Domains A and C of
hRyR21–606 are shown in blue and red, respectively. RyR1 cryo-EM map regions are numbered according to Serysheva et al. (2008). In (a)–(e) the
structural detail is shown in the left panel; a view of the whole RyR2 from the same angle is shown in the right panel. The rectangle corresponds to the
area shown in the left panel.
‘closed’ structure) on the other results from a variance in the
angle between the major axes of domains A and C (Table 5).
This suggests that the 2xoa RyR1 structure might be partially
open while all the RyR2 structures are in the closed state. The
4l4i and 4jkq structures differed from other experimentally
determined structures (2xoa and 4l4h) by a small but signifi-
cant variation in the angle (2) between the minor axes of
domains A and B. These values, however, were not signifi-
cantly different from that of the ‘closed’ RyR structure, but
they were significantly larger than the respective value for the
‘open’ RyR structure. These data suggest that all three
structures of the RyR2 N-terminal region represent the closed
state of the receptor.
4. Discussion
In this study, we present the X-ray structure of the N-terminal
part (amino acids 1–606) of human RyR2 at 2.38 A˚ resolution
and its low-resolution structure in solution. We have also
performed CD analysis of the RyR2 N-terminal region with
the individual mutations P164S, R176Q, I419F and R420W
that are responsible for inherited cardiac arrhythmias (http://
www.fsm.it/cardmoc/) and of the I419F/R420W double
mutant. For the I419F, R420W and I419F/R420W mutants,
thermal stability curves were also measured. The hRyR2
N-terminal structure was docked into the cryo-EM map of the
open and closed conformation of the native skeletal RyR1
isoform.
The recombinant hRyR21–606 fragment was purified and
crystallized at physiological pH and salt concentration (see
x2). Importantly, the high chloride concentration previously
reported to be crucial for solubility and sample homogeneity
of mRyR2 (Kimlicka, Lau et al., 2013) was not necessary for
hRyR21–606. The hRyR21–606 X-ray structure provides new
details that were not observed in the previously solved RyR
N-terminal structures. The structure is in agreement with the
results obtained by limited proteolysis of hRyR21–606 frag-
ments (Bauerova´-Hlinkova´ et al., 2010), since the positions of
loops encompassing Thr259 and Met348 are solvent-acces-
sible.
The structure of individual domains in the RyR1 and RyR2
isoforms (PDB entries 2xoa, 4jkq and 4l4h) is almost identical
but their relative positions showed substantial shifts as
revealed by superposition of the C atoms of individual
domains (Table 2). The direction of the shifts differed from
those found in the structure of the IP3R N-terminal region
upon InsP3 binding, as well as from those induced by docking
into cryo-EM maps of open and closed RyRs (Table 5).
Therefore, the observed main chain shifts most probably do
not reflect N-terminal domain movements occurring during
the process of channel gating. We attribute these shifts
predominantly to differences in purification and crystallization
conditions; both mRyR21–547 (Kimlicka, Tung et al., 2013) and
oRyR11–559 (Tung et al., 2010) structures were obtained at a
higher salt concentration (250 mM KCl and 1.2–1.5 M
ammonium sulfate, respectively), which could produce these
differences.
The mRyR21–547 and hRyR21–606 structures adopt a dispa-
rate arrangement of residues surrounding the previously
proposed chloride-binding site (Kimlicka, Tung et al., 2013). In
hRyR21–606 this site is comprised predominantly of Arg417,
Arg276 and Tyr125 side chains that form a net of interdomain
interactions that do not match those described for
mRyR21–547, but resemble those observed in oRyR1 (Tung et
al., 2010). Despite the presence of NaCl during purification
and crystallization of hRyR21–606, no chloride was observed in
the vicinity of the aforementioned residues in hRyR21–606,
suggesting that the hRyR2 N-terminus has a rather low
propensity to form the chloride-binding site in contrast to that
observed for mRyR21–547 (Kimlicka, Tung et al., 2013). The
presence or absence of the chloride ion in the experimental
solutions did not affect the thermal stability of hRyR21–606 as
shown by thermal shift assay experiments (Borko et al., 2013).
Notably, the cytosolic chloride concentration of cardiac
myocytes is low (	23 mM; Akar et al., 2003) and chloride-
binding sites tend to have affinities in the millimolar range (for
example a Kd of 	0.6 mM in a neurotransmitter transporter
homologue was observed; Tavoulari et al., 2011). These data,
together with our present observations indicating no evidence
of an anion-binding site in the hRyR2 N-terminus, collectively
suggest that the physiological importance and specificity of the
proposed chloride-binding site in RyR2 (Kimlicka, Tung et al.,
2013) remains to be demonstrated.
The SAXS analysis in solution confirmed the overall shape
of the molecule and provided useful information on the
missing C-terminal ‘tail’ of the hRyR21–606 structure (amino
acids 545–606). Secondary-structure analysis of hRyR21–606
and CD spectroscopy of hRyR2 N-terminal fragments of
various lengths (Bauerova´-Hlinkova´ et al., 2010, 2011), as well
as the CD spectra presented here strongly suggest that the
C-terminal tail is composed of -helices that, however, were
not folded into a globular shape. The last resolved residue of
the crystal structure (Asn544) correlates with the last resolved
residue of oRyR11–559 (Gly532; PDB entry 2xoa, a difference
of one amino acid), in which 24 C-terminal residues have
similarly not been resolved. One possibility is that the tail may
be cleaved by a protease, since there are a few protease cutting
sites around residue 545 (PeptideCutter; Wilkins et al., 1999).
However, taking into account the stability of hRyR21–606 in
solution (Borko et al., 2013), the proposal that the C-terminal
part is removed specifically after protease cleavage appears
implausible.
Alternatively, the unresolved C-terminal residues of
hRyR21–606 (545–606) may be present in the crystal but are not
seen owing to inherent flexibility. This hypothesis is based on
two observations: firstly, the shape of the SAXS envelope
suggests that these residues form a tail in solution and,
secondly, a cavity is present at the C-termini of the four
symmetry-related neighbouring molecules in the crystal. The
cavity has a cross-section of approximately 53  48 A˚
(Supplementary Fig. S5) that is large enough to accommodate
the missing C-terminal tails, suggesting that the hRyR21–606
molecule in the crystal is complete. Apparently the flexible
tails form no additional contacts with either the globular
research papers
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part of the hRyR21–606 structure or with themselves, resulting
in a low and non-interpretable electron density in the
cavity. A similar cavity can be observed also in the 2xoa
structure.
Disulfide-bond formation has recently been shown to play
an important role in homotetramer formation by the RyR2
N-terminal region (Zissimopoulos et al., 2013), a property that
is conserved in the IP3Rs (Zissimopoulos et al., 2014). Of the
ten cysteines in the structure of hRyR21–606, only the SH
groups of Cys47 and Cys132 are solvent-accessible. The
homology model of hRyR21–606 predicts a surface location for
SH groups of two further cysteines: Cys548 and Cys577.
Docking of the hRyR2 structure into the cryo-EM density
map of RyR1 reveals that none of these cysteines are located
at the intermolecular interfaces of the hRyR21–606 homo-
tetramer. Based on the hRyR21–606 structure, we suggest that
owing to their relative proximity, S—S bond formation could
potentially occur only between Cys36 and Cys65 or between
Cys131 and Cys158, since involvement of the remaining
cysteines appears sterically unfeasible. Considering that these
putative disulfide bonds are present within each subunit (i.e.
intramolecular) and that such disulfides were empirically
observed to stabilize the association between adjacent sub-
units in the expressed N-terminal tetramer (Zissimopoulos et
al., 2013), this suggests that they may exert their effect on
RyR2 oligomerization via an allosteric effect. Such an allos-
terically acting redox sensor of ryanodine receptor gating
has been proposed previously (Pessah & Feng, 2000). This
possibility could be tested by examining the effect of the
above-mentioned cysteine mutants on the stability of RyR2
tetramerization.
Knowledge of the hRyR21–606 structure gives us an oppor-
tunity to better understand structure–function relationships of
several arrhythmogenic disease-associated mutations,
including P164S, R176Q, I419F, R420W and the double mutant
I419F/R420W (Supplementary Table S1). In the hRyR21–606
structure, Pro164 has a standard conformation at the end of a
-strand. It is followed by a loop, and since its side chain is
similar in size to that of serine, the P164S mutation should not
cause any steric clashes in this region. Arg176 is located in a
loop; its main-chain O atom makes several hydrogen bonds to
main-chain N atoms of neighbouring residues and its guani-
dine group points into solution, forming a stacking interaction
with that of Arg169. Its replacement with glutamine in the
R169Q mutant diminishes the size of the side chain, reduces
the positive charge and removes the stacking interaction. In
contrast, Arg176 is located on the surface of hRyR21–606; its
mutation should not cause structural changes. The effect of the
above mutations will be better understood only in the context
of the interfacing residues of the whole RyR molecule, which
are currently not known.
Ile419 is located in the central -helix. It is buried and forms
contacts with Thr415, Ala416, Leu488, Glu492, Phe489 and
Met494 (Table 4). Replacement of Ile with the bulkier Phe
residue results in profound steric clashes with neighbouring
residues in all rotamers, and this is consistent with the
decreased thermal stability of the mutated hRyR2 fragment
and therefore may be the cause of the severe cardiac
dysfunction in the I419F mutant.
Secondary-structure prediction indicates that the central
helix may undergo a structural change upon the R420W
mutation. The decrease in -helicity observed in CD spectra
for the R420W mutant supports this prediction. However, the
side chain of Arg420 is partially solvent-accessible; it is
therefore likely that the tryptophan side chain in the R420W
mutant adopts a conformation pointing to the solvent, thus
avoiding significant structural changes (Fig. 6c). This is
supported by the unchanged thermal stability of R420W with
respect to that of the wild type (Fig. 7a) and the R420Q
mutant (Kimlicka, Tung et al., 2013). Arg420 is not conserved
between the RyR isoforms, but it is well conserved among
RyR2s from different organisms. The existence of two
different (W/Q) mutations of Arg420 also indicates its
potentially important role.
We have shown by docking of the hRyR21–606 model into a
cryo-EM map of RyR1 (Samso´ et al., 2009) that the LIZ motif
involved in binding of spinophilin–PP1 (Marx et al., 2001) is
most likely to be exposed on the surface of the valley formed
between RyR regions 2b and 5 (Serysheva et al., 2008), and
that spinophilin and PP1 (PDB entry 3egg; Ragusa et al., 2011)
adopt a specific conformation in which the PP1 surface
topology accurately complements that of the RyR surface.
Elucidating the structure of the RyR2–PP1 complex would be
important to help unravel the molecular mechanism of RyR2
dephosphorylation. Understanding the structure and function
of this fundamental regulatory process in muscle excitation–
contraction coupling may be vital in delivering therapeutic
strategies for the prevention of hRyR2 phosphorylation-
related myocardial pathologies, such as mutation-induced and
heart failure-induced tachyarrhythmias and sudden cardiac
death.
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